Harnessing the Microbiome for Disease Prevention and Therapy

Web Desc
MEETING CHANGE TO VIRTUAL: Harnessing the Microbiome for Disease Prevention and Therapy
joint with MEETING CHANGE TO VIRTUAL: The Microbiome: From Mother to Child
Scientific Organizers: Eric G. Pamer, Laurie E. Comstock and Alan Walker
Date: January 17 - 21, 2021
Location: Virtual at your computer
Supported by the Directors' Fund
For important information on the coronavirus, please click here
Summary of Meeting:
Our understanding of the microbiome is advancing rapidly, and continues to productively move through the discovery phase, with numerous correlations being established between specific commensal microbes or microbiota compositions and a wide range of diseases that includes infections, inflammatory conditions, metabolic disease, autoimmunity and neurologic syndromes. The initial discovery of these potentially important correlations has led many laboratories around the world to probe the molecular mechanisms that form the causal link between specific commensal microbes and disease development, progression and resolution. Although there have been great advances, culturing many of the prevalent and metabolically active obligate anaerobic commensals remains a challenge. Exciting advances, however, are emerging from laboratories developing tools to genetically manipulate key commensal organisms, facilitating experimental studies that are identifying the small, bioactive molecules they produce, some of which have therapeutic potential. Studies of the impact of bacteriophage on the microbiota also suggest that they may have therapeutic potential. This Keystone conference will focus on recent advances that demonstrate, at the cellular and molecular level, the impact of the microbiota and its products on disease susceptibility/resistance, with an emphasis on microbial and host metabolism, inter-microbial interactions and the amelioration of diseases.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI154725-01
Funding for this conference was made possible (in part) by 1R13AI154725-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found